W.A.M. Vingerhoets

Sylvester, A. L., Spapens, J. C. C., Tse, D. H. Y., Serrarens, C., Kappert, S., Soons, N., Poser, B. A., Linden, D. E. J., Ivanov, D., van Amelsvoort, T., & Vingerhoets, C. (2026). Effects of riluzole on excitation-inhibition imbalance and functional connectivity in 22q11.2 deletion syndrome: a multimodal 7-Tesla MRI study. Psychiatry Research-Neuroimaging, 362, Article 112279. Advance online publication. https://doi.org/10.1016/j.pscychresns.2026.112279

Kroll, C. F., Leibold, N. K., Vingerhoets, C., Kenis, G., van den Hove, D. L. A., Riedl, A., Schruers, K. R. J., & Hernaus, D. (2026). Variation in DNA methylation of the oxytocin gene is associated with prosocial, reward-related, decision-making. Psychoneuroendocrinology, 188, Article 107815. https://doi.org/10.1016/j.psyneuen.2026.107815

Kroll, C. F., Schruers, K. R. J., Viechtbauer, W., Vingerhoets, C., Seidel, L., Riedl, A., & Hernaus, D. (2026). Absence of a meaningful effect of intranasal oxytocin on trusting behavior: a registered report with pooled equivalence testing. Cortex, 198, 208-233. https://doi.org/10.1016/j.cortex.2026.03.006

Sylvester, A. L., Spapens, J. CC., Soons, N., Kappert, S., Janssen, P., Ivanov, D., Zinkstok, J. R., Linden, D. EJ., van Amelsvoort, T., & Vingerhoets, C. (2026). Efficacy of glutamate-GABA modulator riluzole for the treatment of cognitive and psychotic symptoms in 22q11.2 deletion syndrome: A placebo-controlled crossover trial. Psychiatry Research, 356, Article 116913. https://doi.org/10.1016/j.psychres.2025.116913

D’Incal, C. P., Dierckx, B., Vingerhoets, C., van Haelst, M., Annear, D. J., Van Dijck, A., Bastini, L., Konings, A., Elinck, E., Mateiu, L., van Eeghen, A. M., & Kooy, R. F. (2026). Correction: A missense variant in the KH0-domain of FMRP downregulates the protein in a patient with the clinical hallmarks of fragile X syndrome (European Journal of Human Genetics, (2025), 33, 12, (1596-1605), 10.1038/s41431-025-01967-x). European Journal of Human Genetics. Advance online publication. https://doi.org/10.1038/s41431-026-02095-w

Latrèche, C., Mancini, V., Dvojakovska, M., Kushan, L., Mchangama, F., Tair, F., Cohen, T., Spapens, J., Reijn, L., Díaz-Caneja, C. M., Acheampong, H., Troch, L., Vergaelen, E., Vogels, A., Swillen, A., Vingerhoets, C., Boot, E., Arango, C., Velders, F., ... Eliez, S. (2025). Multicenter retrospective study on effectiveness, reported side effects, and cognitive outcomes of SSRIs in 22q11.2 deletion syndrome. Research Square. Advance online publication. https://doi.org/10.21203/rs.3.rs-8286229/v1

D'Incal, C. P., Dierickx, B., Vingerhoets, C., van Haelst, M., Annear, D. J., Van Dijck, A., Bastini, L., Konings, A., Elinck, E., Mateiu, L., van Eeghen, A. M., & Kooy, R. F. (2025). A missense variant in the KH0-domain of FMRP downregulates the protein in a patient with the clinical hallmarks of fragile X syndrome. European Journal of Human Genetics, 33(12), 1596-1605. https://doi.org/10.1038/s41431-025-01967-x

Snihirova, Y., van Amelsvoort, T., Swillen, A., van den Bree, M., van der Meer, D., Harwood, J., Vingerhoets, C., & Linden, D. E. J. (2025). Parental Education Predicts Longitudinal IQ Trajectories in 22q11.2 Deletion Syndrome: A Three-Cohort European Study. Journal of Intellectual Disability Research, 69(11), 1304-1314. https://doi.org/10.1111/jir.70025

Leijdesdorff, S. M. J., Zwaanswijk, M., & Vingerhoets, C. (2025). Transitioning into adulthood with mild intellectual disability and mental health problems: experiences of young people and parents. International Journal of Developmental Disabilities. Advance online publication. https://doi.org/10.1080/20473869.2025.2555953

Vingerhoets, C., Sylvester, A., Spapens, J., Tse, D., Serrarens, C., Janssen, P., & van Amelsvoort, T. A. M. J. (2025). Anxiolytic Effects of Riluzole in 22q11.2 Deletion Syndrome. Journal of Intellectual Disability Research, 69(9), 745-745.